A researcher conducts testing for antimicrobial resistance. Photo by: Will Crowne / DFID / CC BY

Despite its magnitude, lack of access to antibiotics is a largely overlooked public health issue. 5.7 million people, including 1 million children, are dying annually from antibiotic-treatable conditions because they cannot access the necessary antibiotics in time.

When I worked as a front-line doctor in South Sudan, I saw firsthand how lack of antibiotics threatened lives and the core foundations of modern medicine. I distinctly remember Adut, a teenager living in a small village in the south of the country, who developed a severe bacterial infection in her womb following a miscarriage. The local health center did not have the antibiotics she needed, and it took several days for her to travel to our hospital to get them. By the time she arrived, it was already too late: Her uterus had become septic and she had to have surgery to remove it. While Adut’s life was saved, she was told that she would never be able to become pregnant again.

Opinion: Global solidarity key to tackling superbugs

AMR is on the rise worldwide. While mutant superbugs do grab international attention, the challenge now is to translate multilateral discussions into the concrete action that is urgently needed.

To increase access to antibiotics to avoid what happened to Adut happening to others, we need a three-pronged approach: increase the availability of antibiotics, ensure they are appropriately used, and partner with relevant stakeholders to remove barriers to access.

Here is how.

First, to increase availability, we need to ensure that any novel antibiotics we research and develop are registered in more countries. Of 21 newly developed antibiotics between 1999-2014, less than five were registered in the majority of countries in sub-Saharan Africa. Pharmaceutical companies should work with all stakeholders to ensure registration costs are not a barrier. Once medicines are registered, they should also be made available. In some Indian states, antibiotics are only available in public health facilities half of the time. In Europe and North America, medicine shortages have reached an all-time high.

For both novel and off-patent antibiotics, we must ensure that disruptions to supply chains do not adversely impact their access. Businesses frequently experience disruptions in their supply chains, ranging from supplier delays due to capacity and operational constraints as well as shortages in active pharmaceutical ingredients. Any manufacturing delays impact the downstream stages of production, ultimately leading to shortages and stock-outs.

Many of these shortages and stock-outs are a consequence of the consolidation of manufacturing of raw materials for antibiotics around a few companies, many of which are in China or India. For example, an explosion at a Chinese factory in 2016 triggered an ongoing global shortage of the key broad-spectrum antibiotic piperacillin tazobactam in a number of countries, from high- to low-income.

Secondly, we need to ensure that all antibiotics available on the market are of high quality and appropriately used. One in 10 medical products in low- and middle-income countries are estimated to be substandard or falsified, undermining access to high-quality drugs and further contributing to the spread of drug-resistant infections. Companies are, therefore, investing in preemptive measures, such as tamper-proof packaging, product serialization, and the establishment of anticounterfeit teams.

A global hub for antimicrobial resistance is taking shape

Germany is funding a research center to coordinate efforts to fight antimicrobial resistance. Here's what it's doing first.

To ensure appropriate use, we need to promote best practices in prescribing and dispensing. It is exciting to see the life sciences industry engaging in antimicrobial resistance public education and sharing research and development information to support innovation and surveillance data to track resistance.

Yet the growing prevalence of AMR — experts warn that 10 million people could die by 2050 of drug-resistant diseases — means that antibiotics, which were once very effective, are becoming increasingly ineffective. This puts additional pressure on health care systems, which are faced with a higher number of patients requiring hospitalizations and specialized care when initial treatments fail.

Ultimately, we need to use all the weapons in our arsenal to ensure that antibiotics stay effective for as long as they can.

Improving access to high-quality and affordable diagnostic tools across LMICs will be crucial in reducing the inappropriate prescription of antimicrobials. It is also important that we increase the uptake and coverage of AMR-relevant vaccines because this will allow us to prevent many bacterial and viral infections and therefore reduce the use of antibiotics.

Lastly, no single entity can tackle the lack of access to antibiotics on its own, so we must focus on building and strengthening new and existing partnerships.

Companies must and should work closely with governments and NGOs to break down barriers to access to antibiotics by having partners leverage their unique strengths. That’s why it is significant that a diverse coalition of biotechnology, diagnostics, generics, and large research-based biopharmaceutical companies and associations — the AMR Industry Alliance — has come together to add their expertise and resources to the fight against AMR.

Focusing its work on four key areas, alliance members are investing in research and science, ensuring responsible environmental manufacturing, guaranteeing appropriate use of antibiotics, and tackling the access challenge. Alliance members cover only one-third of the global supply chain for antimicrobials. More companies need to join their ranks now in order to win the fight against the rapid spread of AMR.

Lack of access to antibiotics is a serious medical and equity challenge. Fortunately, we can all take concrete actions to ensure patients like Adut can access the antibiotics they need.

The views in this opinion piece do not necessarily reflect Devex's editorial views.

About the author

  • Serufusa Sekidde

    Serufusa Sekidde is a board member of the AMR Industry Alliance, a group of over 100 organizations from the biotech, diagnostics, generics, and research-based pharmaceutical industry, making it the largest private sector coalition committed to tackling antimicrobial resistance. He is a medical doctor and currently director of Antimicrobial Resistance Policy & Partnerships at GSK in London, U.K.